Related Experiment Video
Updated: Jul 24, 2025
Isolation of Group 2 Innate Lymphoid Cells from Mouse Nasal Mucosa to Detect the Expression of CD226
Published on: May 10, 2022
Modulating ILC2 function for treatment of type 2 airway diseases
Yung-An Huang1,2, Allyssa Strohm1,2, Taylor Doherty1,2
1Section of Allergy and Immunology, Department of Medicine, University of California San Diego.
Group 2 innate lymphoid cells (ILC2s) drive type 2 airway diseases by releasing inflammatory cytokines. Understanding ILC2s offers new therapeutic targets for conditions like asthma and allergic rhinitis.
Area of Science:
- Immunology
- Pulmonology
- Allergy and Clinical Immunology
Background:
- Type 2 airway diseases, including asthma and allergic rhinitis, involve uncontrolled type 2 immune responses.
- These conditions are characterized by elevated type 2 cytokines (IL-4, IL-5, IL-13), eosinophilic inflammation, and tissue remodeling.
- Group 2 innate lymphoid cells (ILC2s) are increasingly recognized for their role in type 2 airway diseases.
Purpose of the Study:
- To review the pathogenesis of ILC2-mediated airway diseases.
- To discuss current and potential therapeutic strategies targeting ILC2s.
Main Methods:
- This is a review article, synthesizing existing research on ILC2s and type 2 airway diseases.
- Literature search on ILC2 function, type 2 immunity, and treatment modalities.
Main Results:
- ILC2s are tissue-resident lymphocytes that respond to epithelial alarmins like TSLP and IL-33.
- Upon activation, ILC2s secrete type 2 cytokines, contributing to airway inflammation and remodeling.
- ILC2 responses can be independent of T cells and may exhibit corticosteroid resistance.
Conclusions:
- ILC2s play a critical role in the pathogenesis of type 2 airway diseases.
- Targeting ILC2 activation or their secreted cytokines presents a promising avenue for novel therapies.
- Further research is needed to develop effective treatments that address ILC2-mediated inflammation.
More Related Videos
10:39Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy
Published on: April 16, 2019
08:16An IL-8 Transiently Transgenized Mouse Model for the In Vivo Long-term Monitoring of Inflammatory Responses
Published on: July 7, 2017
Related Concept Videos
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
01:26Asthma-II: Pathophysiology and Classification
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
01:17Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
01:20Asthma: Pathogenesis and Management
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...